A pan-cancer-bioinformatic-based literature review of TRPM7 in cancers

Liu, Hengrui; Dilger, James P.; Lin, Jun

doi:10.1016/j.pharmthera.2022.108302

Cited by 27 publications

(14 citation statements)

References 158 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Abnormal TRPM7 activity has been implicated in hypertension, cardiac fibrosis, inflammation and atrial fibrillation (AF) (16)(17)(18)(19), with TRPM7 downregulation promoting cardiovascular injury. On the other hand, aberrant expression of TRPM7 has been identified in various tumors, suggesting its significant involvement in tumorigenesis and cancer development (20)(21)(22)(23)(24)(25)(26)(27)(28).…”

mentioning

confidence: 99%

Cardiovascular toxicity of tyrosine kinase inhibitors during cancer treatment: Potential involvement of TRPM7

Liu

Qiu

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Receptor tyrosine kinases (RTKs) are a class of membrane spanning cell-surface receptors that transmit extracellular signals through the membrane to trigger diverse intracellular signaling through tyrosine kinases (TKs), and play important role in cancer development. Therapeutic approaches targeting RTKs such as vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), and platelet-derived growth factor receptor (PDGFR), and TKs, such as c-Src, ABL, JAK, are widely used to treat human cancers. Despite favorable benefits in cancer treatment that prolong survival, these tyrosine kinase inhibitors (TKIs) and monoclonal antibodies targeting RTKs are also accompanied by adverse effects, including cardiovascular toxicity. Mechanisms underlying TKI-induced cardiovascular toxicity remain unclear. The transient receptor potential melastatin-subfamily member 7 (TRPM7) is a ubiquitously expressed chanzyme consisting of a membrane-based ion channel and intracellular α-kinase. TRPM7 is a cation channel that regulates transmembrane Mg2+ and Ca2+ and is involved in a variety of (patho)physiological processes in the cardiovascular system, contributing to hypertension, cardiac fibrosis, inflammation, and atrial arrhythmias. Of importance, we and others demonstrated significant cross-talk between TRPM7, RTKs, and TK signaling in different cell types including vascular smooth muscle cells (VSMCs), which might be a link between TKIs and their cardiovascular effects. In this review, we summarize the implications of RTK inhibitors (RTKIs) and TKIs in cardiovascular toxicities during anti-cancer treatment, with a focus on the potential role of TRPM7/Mg2+ as a mediator of RTKI/TKI-induced cardiovascular toxicity. We also describe the important role of TRPM7 in cancer development and cardiovascular diseases, and the interaction between TRPM7 and RTKs, providing insights for possible mechanisms underlying cardiovascular disease in cancer patients treated with RTKI/TKIs.

show abstract

mentioning

confidence: 99%

Cardiovascular toxicity of tyrosine kinase inhibitors during cancer treatment: Potential involvement of TRPM7

Liu

Qiu

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“… 1 , 6 , 8 , 10 - 12 Accordingly, inhibition of TRPM7 currents by pharmacological compounds has been shown to suppress the proliferation of various cancer cell types in vitro and in animal disease models. 13 - 17 Collectively, these findings identified TRPM7 as an emerging anti-tumor drug target. 13 - 17 …”

Section: Introductionmentioning

confidence: 94%

“… 13 - 17 Collectively, these findings identified TRPM7 as an emerging anti-tumor drug target. 13 - 17 …”

Section: Introductionmentioning

confidence: 94%

Structural basis of selective TRPM7 inhibition by the anticancer agent CCT128930

Nadezhdin,

Correia,

Shalygin

et al. 2024

Cell Reports

View full text Add to dashboard Cite

“…Furthermore, TRPM7 is implicated in gastric cancer, pancreatic cancer, prostate cancer, ovarian cancer, and human hypopharyngeal squamous cell carcinoma. 9 Moreover, in addition to its carcinogenic properties, specific TRP channels have been observed to promote the apoptosis of cancer cells. Studies have revealed an inverse correlation between the expression levels of TRPM1 and the metastasis of melanoma, 10 and the absence of TRPM1 in cancer cells results in uncontrolled cell proliferation.…”

Section: Introductionmentioning

confidence: 99%

Genetic and immune identification and functional analysis of TRPM8 as a potential biomarker for pancreatic adenocarcinoma proliferation

Qiao,

Wu,

Wang

2024

Cancer Reports

View full text Add to dashboard Cite

BackgroundPancreatic adenocarcinoma (PAAD), a member of highly lethal malignant tumors, has a poor outcome and extremely poor prognosis. The transient receptor potential (TRP) superfamily, a group of nonselective cation channels, is capable of influencing cellular functions by regulating calcium homeostasis. In addition, it has been shown that TRP channels can also affect various cellular phenotypes by regulating gene transcription levels and are involved in the development of a variety of malignant tumors.AimsIn order to find new therapeutic targets and biomarkers to improve the clinical prognosis of pancreatic cancer, we performed genetic and immunological characterization of TRP channels in PAAD, as well as related functional and prognostic analyses.Methods and ResultsWe investigated the expression, genetic alterations, methylation levels, and immune infiltration levels of TRP channels in PAAD, and further also analyzed the function of TRP channels in PAAD and their prognostic value for PAAD patients. Our results suggest that TRPM8 may contribute to tumor proliferation by controlling the PI3K‐AKT–mTOR signaling pathway in PAAD.ConclusionAfter careful evaluation of the accumulated data, we concluded that TRPM8 has potential as a prognostic indicator and prospective therapeutic target in PAAD.

show abstract

A pan-cancer-bioinformatic-based literature review of TRPM7 in cancers

Cited by 27 publications

References 158 publications

Cardiovascular toxicity of tyrosine kinase inhibitors during cancer treatment: Potential involvement of TRPM7

Cardiovascular toxicity of tyrosine kinase inhibitors during cancer treatment: Potential involvement of TRPM7

Structural basis of selective TRPM7 inhibition by the anticancer agent CCT128930

Genetic and immune identification and functional analysis of TRPM8 as a potential biomarker for pancreatic adenocarcinoma proliferation

Contact Info

Product

Resources

About